CD8A and neoplasm: The results of the phase I clinical trial found that the combination therapy of beraplanin + pembrolizumab was active against MM and HNSCC, and that dual blockade of PD-L1 and Gal-3 enhanced anti-tumor immunity by enhancing CD8+ T-cells, reducing MDSCs, and repolarizing M2→M1 macrophages (88).